A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone

Completed · Phase 2 · Has a placebo group

Conditions studied: Carcinoma, Non-Small-Cell Lung

In brief

This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen

Key facts

Study ID
NCT00265317
Run by
Pfizer
People needed
162
Starts
2006-06-01
Expected to finish
2012-01-01
Last updated by the study team
2013-02-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.